nodes	percent_of_prediction	percent_of_DWPC	metapath
Guanfacine—CYP2C19—Teniposide—lymphatic system cancer	0.183	0.296	CbGbCtD
Guanfacine—CYP2C9—Teniposide—lymphatic system cancer	0.152	0.246	CbGbCtD
Guanfacine—CYP3A4—Cytarabine—lymphatic system cancer	0.0898	0.145	CbGbCtD
Guanfacine—CYP3A4—Teniposide—lymphatic system cancer	0.0885	0.143	CbGbCtD
Guanfacine—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0619	0.1	CbGbCtD
Guanfacine—CYP3A4—Vincristine—lymphatic system cancer	0.0426	0.0689	CbGbCtD
Guanfacine—NISCH—Podofilox—Teniposide—lymphatic system cancer	0.0133	0.71	CbGdCrCtD
Guanfacine—NISCH—Vinblastine—Vincristine—lymphatic system cancer	0.00543	0.29	CbGdCrCtD
Guanfacine—Renal failure acute—Mitoxantrone—lymphatic system cancer	0.00226	0.00623	CcSEcCtD
Guanfacine—Agitation—Teniposide—lymphatic system cancer	0.00221	0.00608	CcSEcCtD
Guanfacine—Alopecia—Fludarabine—lymphatic system cancer	0.00214	0.0059	CcSEcCtD
Guanfacine—Pain in extremity—Vincristine—lymphatic system cancer	0.00214	0.0059	CcSEcCtD
Guanfacine—Hypertension—Teniposide—lymphatic system cancer	0.00208	0.00571	CcSEcCtD
Guanfacine—Liver function test abnormal—Carmustine—lymphatic system cancer	0.00207	0.00571	CcSEcCtD
Guanfacine—Chest pain—Teniposide—lymphatic system cancer	0.00205	0.00563	CcSEcCtD
Guanfacine—Confusional state—Teniposide—lymphatic system cancer	0.00198	0.00545	CcSEcCtD
Guanfacine—Oedema—Teniposide—lymphatic system cancer	0.00196	0.0054	CcSEcCtD
Guanfacine—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00196	0.0054	CcSEcCtD
Guanfacine—Ill-defined disorder—Fludarabine—lymphatic system cancer	0.00196	0.0054	CcSEcCtD
Guanfacine—Acute coronary syndrome—Bleomycin—lymphatic system cancer	0.00195	0.00538	CcSEcCtD
Guanfacine—Myocardial infarction—Bleomycin—lymphatic system cancer	0.00194	0.00535	CcSEcCtD
Guanfacine—Agitation—Fludarabine—lymphatic system cancer	0.00194	0.00535	CcSEcCtD
Guanfacine—Dysphagia—Carmustine—lymphatic system cancer	0.00194	0.00534	CcSEcCtD
Guanfacine—Tachycardia—Teniposide—lymphatic system cancer	0.00191	0.00527	CcSEcCtD
Guanfacine—Abdominal pain upper—Mitoxantrone—lymphatic system cancer	0.00191	0.00525	CcSEcCtD
Guanfacine—Malaise—Fludarabine—lymphatic system cancer	0.0019	0.00525	CcSEcCtD
Guanfacine—Hyperhidrosis—Teniposide—lymphatic system cancer	0.0019	0.00522	CcSEcCtD
Guanfacine—Pruritus—Mechlorethamine—lymphatic system cancer	0.00188	0.00518	CcSEcCtD
Guanfacine—Alanine aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00184	0.00507	CcSEcCtD
Guanfacine—Hypotension—Teniposide—lymphatic system cancer	0.00183	0.00505	CcSEcCtD
Guanfacine—Convulsion—Fludarabine—lymphatic system cancer	0.00183	0.00504	CcSEcCtD
Guanfacine—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00182	0.00501	CcSEcCtD
Guanfacine—Arthralgia—Fludarabine—lymphatic system cancer	0.0018	0.00495	CcSEcCtD
Guanfacine—Myalgia—Fludarabine—lymphatic system cancer	0.0018	0.00495	CcSEcCtD
Guanfacine—Discomfort—Fludarabine—lymphatic system cancer	0.00178	0.00489	CcSEcCtD
Guanfacine—Dyspnoea—Teniposide—lymphatic system cancer	0.00175	0.00482	CcSEcCtD
Guanfacine—Confusional state—Fludarabine—lymphatic system cancer	0.00174	0.00479	CcSEcCtD
Guanfacine—Oedema—Fludarabine—lymphatic system cancer	0.00172	0.00475	CcSEcCtD
Guanfacine—Erectile dysfunction—Vincristine—lymphatic system cancer	0.00171	0.0047	CcSEcCtD
Guanfacine—Decreased appetite—Teniposide—lymphatic system cancer	0.00171	0.0047	CcSEcCtD
Guanfacine—Vomiting—Mechlorethamine—lymphatic system cancer	0.00169	0.00466	CcSEcCtD
Guanfacine—Rash—Mechlorethamine—lymphatic system cancer	0.00168	0.00462	CcSEcCtD
Guanfacine—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00168	0.00462	CcSEcCtD
Guanfacine—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00167	0.00459	CcSEcCtD
Guanfacine—Erectile dysfunction—Mitoxantrone—lymphatic system cancer	0.00166	0.00457	CcSEcCtD
Guanfacine—Weight increased—Mitoxantrone—lymphatic system cancer	0.00164	0.00452	CcSEcCtD
Guanfacine—Acute coronary syndrome—Vincristine—lymphatic system cancer	0.00163	0.00448	CcSEcCtD
Guanfacine—Myocardial infarction—Vincristine—lymphatic system cancer	0.00162	0.00446	CcSEcCtD
Guanfacine—Feeling abnormal—Teniposide—lymphatic system cancer	0.00162	0.00445	CcSEcCtD
Guanfacine—Drowsiness—Mitoxantrone—lymphatic system cancer	0.00161	0.00443	CcSEcCtD
Guanfacine—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.0016	0.00442	CcSEcCtD
Guanfacine—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.00159	0.00437	CcSEcCtD
Guanfacine—Sweating—Vincristine—lymphatic system cancer	0.00158	0.00436	CcSEcCtD
Guanfacine—Nausea—Mechlorethamine—lymphatic system cancer	0.00158	0.00435	CcSEcCtD
Guanfacine—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.00158	0.00434	CcSEcCtD
Guanfacine—Alopecia—Bleomycin—lymphatic system cancer	0.00157	0.00433	CcSEcCtD
Guanfacine—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00157	0.00433	CcSEcCtD
Guanfacine—Conjunctivitis—Mitoxantrone—lymphatic system cancer	0.00156	0.00431	CcSEcCtD
Guanfacine—Abdominal pain—Teniposide—lymphatic system cancer	0.00155	0.00427	CcSEcCtD
Guanfacine—Paraesthesia—Fludarabine—lymphatic system cancer	0.00155	0.00426	CcSEcCtD
Guanfacine—Hallucination—Carmustine—lymphatic system cancer	0.00155	0.00426	CcSEcCtD
Guanfacine—Sweating—Mitoxantrone—lymphatic system cancer	0.00154	0.00425	CcSEcCtD
Guanfacine—Dyspnoea—Fludarabine—lymphatic system cancer	0.00154	0.00423	CcSEcCtD
Guanfacine—Dyspepsia—Fludarabine—lymphatic system cancer	0.00152	0.00418	CcSEcCtD
Guanfacine—Decreased appetite—Fludarabine—lymphatic system cancer	0.0015	0.00413	CcSEcCtD
Guanfacine—Visual impairment—Carmustine—lymphatic system cancer	0.0015	0.00412	CcSEcCtD
Guanfacine—Fatigue—Fludarabine—lymphatic system cancer	0.00149	0.00409	CcSEcCtD
Guanfacine—Hallucination—Vincristine—lymphatic system cancer	0.00148	0.00406	CcSEcCtD
Guanfacine—Constipation—Fludarabine—lymphatic system cancer	0.00147	0.00406	CcSEcCtD
Guanfacine—Bradycardia—Mitoxantrone—lymphatic system cancer	0.00147	0.00405	CcSEcCtD
Guanfacine—Eye disorder—Carmustine—lymphatic system cancer	0.00145	0.004	CcSEcCtD
Guanfacine—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00145	0.00399	CcSEcCtD
Guanfacine—Hypersensitivity—Teniposide—lymphatic system cancer	0.00145	0.00398	CcSEcCtD
Guanfacine—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00144	0.00396	CcSEcCtD
Guanfacine—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00142	0.00391	CcSEcCtD
Guanfacine—Asthenia—Teniposide—lymphatic system cancer	0.00141	0.00388	CcSEcCtD
Guanfacine—Malaise—Bleomycin—lymphatic system cancer	0.0014	0.00385	CcSEcCtD
Guanfacine—Pruritus—Teniposide—lymphatic system cancer	0.00139	0.00382	CcSEcCtD
Guanfacine—Alopecia—Carmustine—lymphatic system cancer	0.00137	0.00378	CcSEcCtD
Guanfacine—Skin exfoliation—Methotrexate—lymphatic system cancer	0.00137	0.00377	CcSEcCtD
Guanfacine—Diarrhoea—Teniposide—lymphatic system cancer	0.00134	0.0037	CcSEcCtD
Guanfacine—Myalgia—Bleomycin—lymphatic system cancer	0.00132	0.00363	CcSEcCtD
Guanfacine—Chest pain—Bleomycin—lymphatic system cancer	0.00132	0.00363	CcSEcCtD
Guanfacine—Alopecia—Vincristine—lymphatic system cancer	0.00131	0.00361	CcSEcCtD
Guanfacine—Discomfort—Bleomycin—lymphatic system cancer	0.0013	0.00359	CcSEcCtD
Guanfacine—Alopecia—Mitoxantrone—lymphatic system cancer	0.00128	0.00351	CcSEcCtD
Guanfacine—Confusional state—Bleomycin—lymphatic system cancer	0.00127	0.00351	CcSEcCtD
Guanfacine—Vision blurred—Carmustine—lymphatic system cancer	0.00127	0.00351	CcSEcCtD
Guanfacine—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00127	0.0035	CcSEcCtD
Guanfacine—Tremor—Carmustine—lymphatic system cancer	0.00127	0.00349	CcSEcCtD
Guanfacine—Oedema—Bleomycin—lymphatic system cancer	0.00126	0.00348	CcSEcCtD
Guanfacine—Vomiting—Teniposide—lymphatic system cancer	0.00125	0.00343	CcSEcCtD
Guanfacine—Agitation—Carmustine—lymphatic system cancer	0.00124	0.00342	CcSEcCtD
Guanfacine—Asthenia—Fludarabine—lymphatic system cancer	0.00124	0.00341	CcSEcCtD
Guanfacine—Rash—Teniposide—lymphatic system cancer	0.00124	0.00341	CcSEcCtD
Guanfacine—Dermatitis—Teniposide—lymphatic system cancer	0.00124	0.0034	CcSEcCtD
Guanfacine—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00123	0.00339	CcSEcCtD
Guanfacine—Headache—Teniposide—lymphatic system cancer	0.00123	0.00338	CcSEcCtD
Guanfacine—Pruritus—Fludarabine—lymphatic system cancer	0.00122	0.00336	CcSEcCtD
Guanfacine—Agitation—Vincristine—lymphatic system cancer	0.00119	0.00327	CcSEcCtD
Guanfacine—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00118	0.00326	CcSEcCtD
Guanfacine—Hypotension—Bleomycin—lymphatic system cancer	0.00118	0.00325	CcSEcCtD
Guanfacine—Diarrhoea—Fludarabine—lymphatic system cancer	0.00118	0.00325	CcSEcCtD
Guanfacine—Convulsion—Carmustine—lymphatic system cancer	0.00117	0.00323	CcSEcCtD
Guanfacine—Hypertension—Carmustine—lymphatic system cancer	0.00117	0.00321	CcSEcCtD
Guanfacine—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00117	0.00321	CcSEcCtD
Guanfacine—Nausea—Teniposide—lymphatic system cancer	0.00117	0.00321	CcSEcCtD
Guanfacine—Vertigo—Vincristine—lymphatic system cancer	0.00116	0.00319	CcSEcCtD
Guanfacine—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00115	0.00317	CcSEcCtD
Guanfacine—Myalgia—Carmustine—lymphatic system cancer	0.00115	0.00317	CcSEcCtD
Guanfacine—Chest pain—Carmustine—lymphatic system cancer	0.00115	0.00317	CcSEcCtD
Guanfacine—Anxiety—Carmustine—lymphatic system cancer	0.00115	0.00316	CcSEcCtD
Guanfacine—Paraesthesia—Bleomycin—lymphatic system cancer	0.00114	0.00313	CcSEcCtD
Guanfacine—Malaise—Mitoxantrone—lymphatic system cancer	0.00113	0.00312	CcSEcCtD
Guanfacine—Dyspnoea—Bleomycin—lymphatic system cancer	0.00113	0.0031	CcSEcCtD
Guanfacine—Renal failure acute—Methotrexate—lymphatic system cancer	0.00113	0.0031	CcSEcCtD
Guanfacine—Convulsion—Vincristine—lymphatic system cancer	0.00112	0.00308	CcSEcCtD
Guanfacine—Hypertension—Vincristine—lymphatic system cancer	0.00111	0.00307	CcSEcCtD
Guanfacine—Confusional state—Carmustine—lymphatic system cancer	0.00111	0.00306	CcSEcCtD
Guanfacine—Oedema—Carmustine—lymphatic system cancer	0.0011	0.00304	CcSEcCtD
Guanfacine—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.0011	0.00303	CcSEcCtD
Guanfacine—Decreased appetite—Bleomycin—lymphatic system cancer	0.0011	0.00303	CcSEcCtD
Guanfacine—Myalgia—Vincristine—lymphatic system cancer	0.0011	0.00303	CcSEcCtD
Guanfacine—Vomiting—Fludarabine—lymphatic system cancer	0.0011	0.00302	CcSEcCtD
Guanfacine—Convulsion—Mitoxantrone—lymphatic system cancer	0.00109	0.003	CcSEcCtD
Guanfacine—Rash—Fludarabine—lymphatic system cancer	0.00109	0.00299	CcSEcCtD
Guanfacine—Dermatitis—Fludarabine—lymphatic system cancer	0.00109	0.00299	CcSEcCtD
Guanfacine—Hypertension—Mitoxantrone—lymphatic system cancer	0.00109	0.00299	CcSEcCtD
Guanfacine—Headache—Fludarabine—lymphatic system cancer	0.00108	0.00297	CcSEcCtD
Guanfacine—Tachycardia—Carmustine—lymphatic system cancer	0.00108	0.00297	CcSEcCtD
Guanfacine—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00107	0.00295	CcSEcCtD
Guanfacine—Chest pain—Mitoxantrone—lymphatic system cancer	0.00107	0.00295	CcSEcCtD
Guanfacine—Myalgia—Mitoxantrone—lymphatic system cancer	0.00107	0.00295	CcSEcCtD
Guanfacine—Anxiety—Mitoxantrone—lymphatic system cancer	0.00107	0.00294	CcSEcCtD
Guanfacine—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.00106	0.00292	CcSEcCtD
Guanfacine—Lethargy—Methotrexate—lymphatic system cancer	0.00106	0.00292	CcSEcCtD
Guanfacine—Discomfort—Mitoxantrone—lymphatic system cancer	0.00106	0.00291	CcSEcCtD
Guanfacine—Oedema—Vincristine—lymphatic system cancer	0.00105	0.0029	CcSEcCtD
Guanfacine—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00104	0.00287	CcSEcCtD
Guanfacine—Confusional state—Mitoxantrone—lymphatic system cancer	0.00103	0.00285	CcSEcCtD
Guanfacine—Hypotension—Carmustine—lymphatic system cancer	0.00103	0.00284	CcSEcCtD
Guanfacine—Oedema—Mitoxantrone—lymphatic system cancer	0.00103	0.00282	CcSEcCtD
Guanfacine—Nausea—Fludarabine—lymphatic system cancer	0.00102	0.00282	CcSEcCtD
Guanfacine—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00102	0.0028	CcSEcCtD
Guanfacine—Shock—Mitoxantrone—lymphatic system cancer	0.00101	0.00278	CcSEcCtD
Guanfacine—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00101	0.00277	CcSEcCtD
Guanfacine—Tachycardia—Mitoxantrone—lymphatic system cancer	0.001	0.00276	CcSEcCtD
Guanfacine—Insomnia—Carmustine—lymphatic system cancer	0.000998	0.00275	CcSEcCtD
Guanfacine—Irritability—Methotrexate—lymphatic system cancer	0.000992	0.00273	CcSEcCtD
Guanfacine—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000992	0.00273	CcSEcCtD
Guanfacine—Paraesthesia—Carmustine—lymphatic system cancer	0.000991	0.00273	CcSEcCtD
Guanfacine—Hypotension—Vincristine—lymphatic system cancer	0.000984	0.00271	CcSEcCtD
Guanfacine—Dyspnoea—Carmustine—lymphatic system cancer	0.000984	0.00271	CcSEcCtD
Guanfacine—Somnolence—Carmustine—lymphatic system cancer	0.000981	0.0027	CcSEcCtD
Guanfacine—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.00096	0.00264	CcSEcCtD
Guanfacine—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00096	0.00264	CcSEcCtD
Guanfacine—Decreased appetite—Carmustine—lymphatic system cancer	0.000959	0.00264	CcSEcCtD
Guanfacine—Hypotension—Mitoxantrone—lymphatic system cancer	0.000958	0.00264	CcSEcCtD
Guanfacine—Insomnia—Vincristine—lymphatic system cancer	0.000953	0.00262	CcSEcCtD
Guanfacine—Paraesthesia—Vincristine—lymphatic system cancer	0.000946	0.0026	CcSEcCtD
Guanfacine—Constipation—Carmustine—lymphatic system cancer	0.000944	0.0026	CcSEcCtD
Guanfacine—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000935	0.00257	CcSEcCtD
Guanfacine—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000931	0.00256	CcSEcCtD
Guanfacine—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000921	0.00254	CcSEcCtD
Guanfacine—Decreased appetite—Vincristine—lymphatic system cancer	0.000916	0.00252	CcSEcCtD
Guanfacine—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000914	0.00252	CcSEcCtD
Guanfacine—Somnolence—Mitoxantrone—lymphatic system cancer	0.000912	0.00251	CcSEcCtD
Guanfacine—Feeling abnormal—Carmustine—lymphatic system cancer	0.000909	0.0025	CcSEcCtD
Guanfacine—Fatigue—Vincristine—lymphatic system cancer	0.000908	0.0025	CcSEcCtD
Guanfacine—Asthenia—Bleomycin—lymphatic system cancer	0.000907	0.0025	CcSEcCtD
Guanfacine—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000903	0.00249	CcSEcCtD
Guanfacine—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000902	0.00248	CcSEcCtD
Guanfacine—Constipation—Vincristine—lymphatic system cancer	0.000901	0.00248	CcSEcCtD
Guanfacine—Asthma—Methotrexate—lymphatic system cancer	0.000899	0.00247	CcSEcCtD
Guanfacine—Pruritus—Bleomycin—lymphatic system cancer	0.000894	0.00246	CcSEcCtD
Guanfacine—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000892	0.00246	CcSEcCtD
Guanfacine—Fatigue—Mitoxantrone—lymphatic system cancer	0.000884	0.00244	CcSEcCtD
Guanfacine—Constipation—Mitoxantrone—lymphatic system cancer	0.000877	0.00242	CcSEcCtD
Guanfacine—Abdominal pain—Carmustine—lymphatic system cancer	0.000872	0.0024	CcSEcCtD
Guanfacine—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.000862	0.00237	CcSEcCtD
Guanfacine—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000861	0.00237	CcSEcCtD
Guanfacine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000845	0.00233	CcSEcCtD
Guanfacine—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000839	0.00231	CcSEcCtD
Guanfacine—Abdominal pain—Vincristine—lymphatic system cancer	0.000833	0.00229	CcSEcCtD
Guanfacine—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000828	0.00228	CcSEcCtD
Guanfacine—Hypersensitivity—Carmustine—lymphatic system cancer	0.000813	0.00224	CcSEcCtD
Guanfacine—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000811	0.00223	CcSEcCtD
Guanfacine—Vomiting—Bleomycin—lymphatic system cancer	0.000804	0.00221	CcSEcCtD
Guanfacine—Drowsiness—Methotrexate—lymphatic system cancer	0.000801	0.00221	CcSEcCtD
Guanfacine—Rash—Bleomycin—lymphatic system cancer	0.000797	0.00219	CcSEcCtD
Guanfacine—Dermatitis—Bleomycin—lymphatic system cancer	0.000796	0.00219	CcSEcCtD
Guanfacine—Asthenia—Carmustine—lymphatic system cancer	0.000792	0.00218	CcSEcCtD
Guanfacine—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000779	0.00214	CcSEcCtD
Guanfacine—Hypersensitivity—Vincristine—lymphatic system cancer	0.000776	0.00214	CcSEcCtD
Guanfacine—Sweating—Methotrexate—lymphatic system cancer	0.000768	0.00212	CcSEcCtD
Guanfacine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000756	0.00208	CcSEcCtD
Guanfacine—Asthenia—Vincristine—lymphatic system cancer	0.000756	0.00208	CcSEcCtD
Guanfacine—Diarrhoea—Carmustine—lymphatic system cancer	0.000755	0.00208	CcSEcCtD
Guanfacine—Nausea—Bleomycin—lymphatic system cancer	0.000751	0.00207	CcSEcCtD
Guanfacine—Asthenia—Mitoxantrone—lymphatic system cancer	0.000736	0.00203	CcSEcCtD
Guanfacine—Dizziness—Carmustine—lymphatic system cancer	0.00073	0.00201	CcSEcCtD
Guanfacine—Diarrhoea—Vincristine—lymphatic system cancer	0.000721	0.00198	CcSEcCtD
Guanfacine—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000702	0.00193	CcSEcCtD
Guanfacine—Vomiting—Carmustine—lymphatic system cancer	0.000702	0.00193	CcSEcCtD
Guanfacine—Dizziness—Vincristine—lymphatic system cancer	0.000696	0.00192	CcSEcCtD
Guanfacine—Rash—Carmustine—lymphatic system cancer	0.000696	0.00192	CcSEcCtD
Guanfacine—Dermatitis—Carmustine—lymphatic system cancer	0.000695	0.00191	CcSEcCtD
Guanfacine—Visual impairment—Methotrexate—lymphatic system cancer	0.000693	0.00191	CcSEcCtD
Guanfacine—Headache—Carmustine—lymphatic system cancer	0.000691	0.0019	CcSEcCtD
Guanfacine—Eye disorder—Methotrexate—lymphatic system cancer	0.000672	0.00185	CcSEcCtD
Guanfacine—Tinnitus—Methotrexate—lymphatic system cancer	0.000671	0.00185	CcSEcCtD
Guanfacine—Vomiting—Vincristine—lymphatic system cancer	0.00067	0.00184	CcSEcCtD
Guanfacine—Rash—Vincristine—lymphatic system cancer	0.000664	0.00183	CcSEcCtD
Guanfacine—Dermatitis—Vincristine—lymphatic system cancer	0.000663	0.00183	CcSEcCtD
Guanfacine—Headache—Vincristine—lymphatic system cancer	0.00066	0.00182	CcSEcCtD
Guanfacine—Nausea—Carmustine—lymphatic system cancer	0.000655	0.0018	CcSEcCtD
Guanfacine—Vomiting—Mitoxantrone—lymphatic system cancer	0.000652	0.0018	CcSEcCtD
Guanfacine—Immune system disorder—Methotrexate—lymphatic system cancer	0.00065	0.00179	CcSEcCtD
Guanfacine—Rash—Mitoxantrone—lymphatic system cancer	0.000647	0.00178	CcSEcCtD
Guanfacine—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000646	0.00178	CcSEcCtD
Guanfacine—Headache—Mitoxantrone—lymphatic system cancer	0.000643	0.00177	CcSEcCtD
Guanfacine—Alopecia—Methotrexate—lymphatic system cancer	0.000636	0.00175	CcSEcCtD
Guanfacine—Nausea—Vincristine—lymphatic system cancer	0.000626	0.00172	CcSEcCtD
Guanfacine—Dysgeusia—Methotrexate—lymphatic system cancer	0.000613	0.00169	CcSEcCtD
Guanfacine—Nausea—Mitoxantrone—lymphatic system cancer	0.000609	0.00168	CcSEcCtD
Guanfacine—Vision blurred—Methotrexate—lymphatic system cancer	0.00059	0.00163	CcSEcCtD
Guanfacine—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000581	0.0016	CcSEcCtD
Guanfacine—Malaise—Methotrexate—lymphatic system cancer	0.000565	0.00156	CcSEcCtD
Guanfacine—Vertigo—Methotrexate—lymphatic system cancer	0.000563	0.00155	CcSEcCtD
Guanfacine—Convulsion—Methotrexate—lymphatic system cancer	0.000543	0.00149	CcSEcCtD
Guanfacine—Chest pain—Methotrexate—lymphatic system cancer	0.000533	0.00147	CcSEcCtD
Guanfacine—Arthralgia—Methotrexate—lymphatic system cancer	0.000533	0.00147	CcSEcCtD
Guanfacine—Myalgia—Methotrexate—lymphatic system cancer	0.000533	0.00147	CcSEcCtD
Guanfacine—Discomfort—Methotrexate—lymphatic system cancer	0.000527	0.00145	CcSEcCtD
Guanfacine—Confusional state—Methotrexate—lymphatic system cancer	0.000515	0.00142	CcSEcCtD
Guanfacine—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000494	0.00136	CcSEcCtD
Guanfacine—Hypotension—Methotrexate—lymphatic system cancer	0.000478	0.00132	CcSEcCtD
Guanfacine—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000466	0.00128	CcSEcCtD
Guanfacine—Insomnia—Methotrexate—lymphatic system cancer	0.000462	0.00127	CcSEcCtD
Guanfacine—Paraesthesia—Methotrexate—lymphatic system cancer	0.000459	0.00126	CcSEcCtD
Guanfacine—Dyspnoea—Methotrexate—lymphatic system cancer	0.000456	0.00125	CcSEcCtD
Guanfacine—Somnolence—Methotrexate—lymphatic system cancer	0.000454	0.00125	CcSEcCtD
Guanfacine—Dyspepsia—Methotrexate—lymphatic system cancer	0.00045	0.00124	CcSEcCtD
Guanfacine—Decreased appetite—Methotrexate—lymphatic system cancer	0.000444	0.00122	CcSEcCtD
Guanfacine—Fatigue—Methotrexate—lymphatic system cancer	0.000441	0.00121	CcSEcCtD
Guanfacine—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000421	0.00116	CcSEcCtD
Guanfacine—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000418	0.00115	CcSEcCtD
Guanfacine—Abdominal pain—Methotrexate—lymphatic system cancer	0.000404	0.00111	CcSEcCtD
Guanfacine—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000377	0.00104	CcSEcCtD
Guanfacine—Asthenia—Methotrexate—lymphatic system cancer	0.000367	0.00101	CcSEcCtD
Guanfacine—Pruritus—Methotrexate—lymphatic system cancer	0.000362	0.000996	CcSEcCtD
Guanfacine—Diarrhoea—Methotrexate—lymphatic system cancer	0.00035	0.000963	CcSEcCtD
Guanfacine—Dizziness—Methotrexate—lymphatic system cancer	0.000338	0.000931	CcSEcCtD
Guanfacine—Vomiting—Methotrexate—lymphatic system cancer	0.000325	0.000895	CcSEcCtD
Guanfacine—Rash—Methotrexate—lymphatic system cancer	0.000322	0.000887	CcSEcCtD
Guanfacine—Dermatitis—Methotrexate—lymphatic system cancer	0.000322	0.000887	CcSEcCtD
Guanfacine—Headache—Methotrexate—lymphatic system cancer	0.00032	0.000882	CcSEcCtD
Guanfacine—Nausea—Methotrexate—lymphatic system cancer	0.000304	0.000836	CcSEcCtD
